Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppression

References

• Golsteyn RM, Schultz SJ, Bartek J, Ziemiecki A, Ried T, Nigg EA. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 1994; 107 (Pt 6):1509-17; PMID:7962193
   PubMed Web of Science ®Google Scholar
• Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters JM. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007; 17(4):304-15; PMID:17291761; http://dx.doi.org/10.1016/j.cub.2006.12.046
   PubMed Web of Science ®Google Scholar
• Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nature Rev Drug Discovery 2010; 9(8):643-60; http://dx.doi.org/10.1038/nrd3184
   PubMed Web of Science ®Google Scholar
• Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H, Medema RH. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7(2):126-36; PMID:15654331; http://dx.doi.org/10.1038/ncb1217
   PubMed Web of Science ®Google Scholar
• Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005; 24(2):267-76; PMID:15640842; http://dx.doi.org/10.1038/sj.onc.1208273
   PubMed Web of Science ®Google Scholar
• Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6(4):321-30; PMID:16557283; http://dx.doi.org/10.1038/nrc1841
   PubMed Web of Science ®Google Scholar
• Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005; 24(2):287-91; PMID:15640844; http://dx.doi.org/10.1038/sj.onc.1208272
   PubMed Web of Science ®Google Scholar
• Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59(12):2794-7; PMID:10383133
   PubMed Web of Science ®Google Scholar
• Knecht R, Oberhauser C, Strebhardt K. PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer 2000; 89(6):535-6; PMID:11102900; http://dx.doi.org/10.1002/1097-0215(20001120)89:6%3c535::AID-IJC12%3e3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutaneous Pathol 2002; 29(6):354-8; http://dx.doi.org/10.1034/j.1600-0560.2002.290605.x
   PubMed Web of Science ®Google Scholar
• Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R. Prognostic value of pololike kinase expression in melanomas. JAMA 2000; 283(4):479-80; http://dx.doi.org/10.1001/jama.283.4.479
   PubMed Web of Science ®Google Scholar
• Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006; 26(6):2093-108; PMID:16507989; http://dx.doi.org/10.1128/MCB.26.6.2093-2108.2006
   PubMed Web of Science ®Google Scholar
• Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009; 137(5):835-48; PMID:19490893; http://dx.doi.org/10.1016/j.cell.2009.05.006
   PubMed Web of Science ®Google Scholar
• Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 2009; 106(10):3964-9; PMID:19225112; http://dx.doi.org/10.1073/pnas.0813333106
   PubMed Web of Science ®Google Scholar
• Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, Hermann E, Pliquett U, Neumann E, Zeuzem S. Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 2003; 22(1):69-80; PMID:12527909; http://dx.doi.org/10.1038/sj.onc.1206038
   PubMed Web of Science ®Google Scholar
• Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17(4):316-22; PMID:17291758; http://dx.doi.org/10.1016/j.cub.2006.12.037
   PubMed Web of Science ®Google Scholar
• Nie Z, Feher V, Natala S, McBride C, Kiryanov A, Jones B, Lam B, Liu Y, Kaldor S, Stafford J, et al. Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1). Bioorg Med Chem Lett 2013; 23(12):3662-6; PMID:23664874; http://dx.doi.org/10.1016/j.bmcl.2013.02.083
   PubMed Web of Science ®Google Scholar
• Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, Murai S, Uchiyama N, Hasegawa M, Kawamoto T, Sato T, et al. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther 2012; 11(3):700-9; PMID:22188812; http://dx.doi.org/10.1158/1535-7163.MCT-11-0762
   PubMed Web of Science ®Google Scholar
• O'Neill A, Shah N, Zitomersky N, Ladanyi M, Shukla N, Uren A, Loeb D, Toretsky J. Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature. Sarcoma 2013; 2013:450478; PMID:23431249; http://dx.doi.org/10.1155/2013/450478
   PubMedGoogle Scholar
• Singer S, Millis K, Souza K, Fletcher C. Correlation of lipid content and composition with liposarcoma histology and grade. Ann Surg Oncol 1997; 4(7):557-63; PMID:9367021; http://dx.doi.org/10.1007/BF02305536
   PubMed Web of Science ®Google Scholar
• Kar M, Deo SV, Shukla NK, Malik A, DattaGupta S, Mohanti BK, Thulkar S. Malignant peripheral nerve sheath tumors (MPNST)–clinicopathological study and treatment outcome of twenty-four cases. World J Surg Oncol 2006; 4:55
   PubMedGoogle Scholar
• Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev 2008; 9(1):47-59; PMID:18097445; http://dx.doi.org/10.1038/nrm2308
   PubMedGoogle Scholar
• Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011; 471(7336):110-4; PMID:21368834; http://dx.doi.org/10.1038/nature09779
   PubMed Web of Science ®Google Scholar
• Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005; 121(7):1085-95; PMID:15989957; http://dx.doi.org/10.1016/j.cell.2005.06.009
   PubMed Web of Science ®Google Scholar
• Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW, Wei W. Mcl-1 ubiquitination and destruction. Oncotarget 2011; 2(3):239-44; PMID:21608150
   PubMed Web of Science ®Google Scholar
• Stevenson CS, Capper EA, Roshak AK, Marquez B, Eichman C, Jackson JR, Mattern M, Gerwick WH, Jacobs RS. The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J Pharmacol Ex Ther 2002; 303(2):858-66; PMID:12388673; http://dx.doi.org/10.1124/jpet.102.036350
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, Al-Batran SE, Hochhaus A, Jäger E, Reichardt VL, Fritsch H, Trommeshauser D, Munzert G. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 2010; 16(18):4666-74; PMID:20682708; http://dx.doi.org/10.1158/1078-0432.CCR-10-0318
   PubMed Web of Science ®Google Scholar
• Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower RC. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008; 26(34):5504-10; PMID:18955447
   PubMed Web of Science ®Google Scholar
• Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Letters 2010; 584(14):2981-9; PMID:20540941; http://dx.doi.org/10.1016/j.febslet.2010.05.061
   PubMed Web of Science ®Google Scholar
• Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol 1996; 16(3):1126-37
   PubMed Web of Science ®Google Scholar
• Subramanian S, Thayanithy V, West RB, et al. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol 2010; 220(1):58-70; PMID:19890883; http://dx.doi.org/10.1002/path.2633
   PubMed Web of Science ®Google Scholar
• Singer S, Socci ND, Ambrosini G, Lee CH, Beck AH, Zhu S, Downs-Kelly E, Montgomery K, Goldblum JR, Hogendoorn PC, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007; 67(14):6626-36; PMID:17638873; http://dx.doi.org/10.1158/0008-5472.CAN-07-0584
   PubMed Web of Science ®Google Scholar
• Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999; 5(7):1876-83; PMID:10430095
   PubMed Web of Science ®Google Scholar
• Nair JS, de Stanchina E, Schwartz GK. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res 2009; 15(6):2022-30; PMID:19276280; http://dx.doi.org/10.1158/1078-0432.CCR-08-1826
   PubMed Web of Science ®Google Scholar
• Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PloS One 2012; 7(7):e40439; PMID:22808163; http://dx.doi.org/10.1371/journal.pone.0040439
   PubMed Web of Science ®Google Scholar
• Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, Sommer P, Csiszar K, Hendrix MJ. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 2002; 62(15):4478-83; PMID:12154058
   PubMed Web of Science ®Google Scholar
• Lange L, Keppner-Witter S, Grigat J, Spänkuch B. Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status. Oncotarget 2014; 5:2263-75; PMID:24810255
   PubMed Web of Science ®Google Scholar
• Czaplinski S, Hugle M, Stiehl V, Fulda S. Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis. Oncotarget 2015; 5; PMID:26046302
   PubMedGoogle Scholar